← FDA DRUG APPROVALS

FDA ANDA · ANDA205501

TOBRAMYCIN

Sponsor: AMNEAL PHARMS

APPLICATION
ANDA205501
TYPE
ANDA
ORIGINAL APPROVAL
2015-07-13
LATEST ACTION
2023-07-10
ROUTE
RESPIRATORY (INHALATION), INHALATION
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

TOBRAMYCINPrescription
TOBRAMYCIN 300MG/5ML · SOLUTION · INHALATION

Approval history

2023-07-10Labeling · Supplement 13 · standardAP
2020-02-21Labeling · Supplement 5 · standardAP
2015-07-13UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →